יתרות מזומנים בחישוב למניה Scholar Rock Inc. (SRRK)

Scholar Rock - לוגו גרפי של המנפיק SRRK

Scholar Rock is recognized as an authoritative developer of therapies for restoring muscle tone. Cash per share confirms the financial dynamics, where the value is maintained at 3.44. Growth potential is based on the creation of targeted antibodies against myostatin. However, success depends on FDA approval of apitegromab and the cost-effectiveness of its promotion.

מזומנים למניה: Scholar Rock, Inc. (SRRK) עבור 04.07.2022 - 20.11.2026

פילוחים אנליטיים של חברת Scholar Rock

- מחיר שוק ויעדי מחיר של אנליסטים:
- מדדי זמינות כספים ותזרימי מזומנים:
ניתוח מסכם של החברה:SRRK, Scholar Rock Inc.
מוצר מקורי של scholarrock.com

For the biotech sector company Scholar Rock (SRRK), which is developing antibodies for SMA therapy, the amount of liquidity per share determines the margin of safety for funding costly clinical trials. By analyzing the cash per share chart, an investor can see the ratio of total cash reserves to the number of shares, making it possible to distinguish actual asset undervaluation from the systemic depletion of the company's capital.